文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

曲妥珠单抗瑞泽替康治疗ERBB2低表达晚期乳腺癌:HORIZON-Breast06随机临床试验

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-10-23

这项在中国73家医院开展的开放标签3期随机试验纳入551例ERBB2低表达晚期乳腺癌患者,比较曲妥珠单抗瑞泽替康与医生选择的化疗。结果显示,曲妥珠单抗瑞泽替康显著延长无进展生存期,在化疗初治患者和总体人群中均获益,且各关键亚组一致,但≥3级治疗相关不良事件发生率更高。

要点

  • 曲妥珠单抗瑞泽替康较化疗显著延长ERBB2低表达晚期乳腺癌无进展生存期。
  • 化疗初治患者中位无进展生存期16.6个月 vs 6.8个月,HR 0.25。
  • ≥3级治疗相关不良事件发生率84.1%,最常见为中性粒细胞计数降低。

核心结论

  • 曲妥珠单抗瑞泽替康较医生选择的化疗在ERBB2低表达晚期乳腺癌中显著改善无进展生存期,各关键亚组一致获益。

研究设计与样本

  • 开放标签、随机、多中心3期试验,在中国73家医院开展,共随机551例患者。
  • 入组女性年龄18至75岁,中心确认ERBB2低表达(IHC 1+或IHC 2+/ISH阴性)不可切除局部复发或转移性乳腺癌。
  • 患者转移阶段既往化疗线数不超过1线,激素受体阳性者需既往内分泌治疗。
  • 按1:1随机接受曲妥珠单抗瑞泽替康6.4 mg/kg静脉每3周(n=277)或医生选择化疗(n=274)。

主要发现

  • 化疗初治患者中位无进展生存期16.6个月(95%CI 14.0-19.4) vs 6.8个月(95%CI 5.7-7.0),HR 0.25(95%CI 0.19-0.33),P < .001。
  • 总体人群中位无进展生存期16.4个月(95%CI 14.0-16.8) vs 6.8个月(95%CI 5.7-6.9),HR 0.27(95%CI 0.21-0.34),P < .001。
  • 激素受体阴性疾病中位无进展生存期16.5 vs 6.8个月,HR 0.34(95%CI 0.22-0.54)。
  • 激素受体阳性疾病中位无进展生存期16.4 vs 6.7个月,HR 0.24(95%CI 0.18-0.33)。
  • ≥3级治疗相关不良事件发生率84.1%(232/276) vs 67.9%(184/271),最常见为中性粒细胞计数降低(180 [65.2%] vs 147 [54.2%])。

关键数值与推荐

  • ERBB2低表达定义为中心确认的IHC 1+或IHC 2+/ISH阴性。
  • 主要终点为盲态独立中心评估的无进展生存期,在化疗初治患者和总体人群中评估。
  • 曲妥珠单抗瑞泽替康剂量为6.4 mg/kg静脉每3周。

临床怎么用

  • 对于既往化疗不超过1线的ERBB2低表达晚期乳腺癌患者,曲妥珠单抗瑞泽替康可作为新的治疗选择。
  • 使用时需关注≥3级治疗相关不良事件,尤其是中性粒细胞计数降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast cancer. OBJECTIVE: To compare trastuzumab rezetecan vs physician's choice of chemotherapy in patients with ERBB2-low metastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized, multicenter phase 3 trial was conducted at 73 hospitals across China. Eligible patients were females aged 18 to 75 years with centrally confirmed ERBB2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-negative) unresectable locally recurrent or metastatic breast cancer who had received 1 or fewer prior lines of chemotherapy for metastatic disease, with prior endocrine therapy required for hormone receptor-positive disease. Enrollment began on June 30, 2023, and ended on August 20, 2025. The last day of follow-up for the final analysis for progression-free survival in the current study was March 20, 2026. INTERVENTIONS: Patients were randomly assigned (1:1) to receive trastuzumab rezetecan (6.4 mg/kg intravenously every 3 weeks; n = 277) or physician's choice of chemotherapy (n = 274). MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival assessed by blinded independent central review in chemotherapy-naive patients and the overall population. RESULTS: Between June 30, 2023, and August 20, 2025, a total of 551 patients were randomized, with a mean (SD) age of 54.9 (9.9) years. At the data cutoff (March 20, 2026), trastuzumab rezetecan significantly prolonged progression-free survival compared with chemotherapy in the chemotherapy-naive patients (median, 16.6 [95% CI, 14.0-19.4] months vs 6.8 [95% CI, 5.7-7.0] months; hazard ratio, 0.25 [95% CI, 0.19-0.33]; P < .001) and the overall population (median, 16.4 [95% CI, 14.0-16.8] months vs 6.8 [95% CI, 5.7-6.9] months; hazard ratio, 0.27 [95% CI, 0.21-0.34]; P < .001). The benefit was consistent in hormone receptor-negative disease (median progression-free survival: 16.5 vs 6.8 months; hazard ratio, 0.34, [95% CI, 0.22-0.54]) and hormone receptor-positive disease (median progression-free survival: 16.4 vs 6.7 months; hazard ratio, 0.24 [95% CI, 0.18-0.33]). Grade 3 or greater treatment-related adverse events occurred in 84.1% of patients (232/276) with trastuzumab rezetecan and 67.9% (184/271) with chemotherapy, most commonly decreased neutrophil count (180 [65.2%] vs 147 [54.2%]). CONCLUSIONS AND RELEVANCE: Trastuzumab rezetecan provided significant progression-free survival benefit over physician's choice of chemotherapy in patients with ERBB2-low advanced breast cancer, with benefit observed across all key subgroups. It exhibited the potential as a new treatment option with a distinct safety profile in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05814354.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Fan Y, Liu Y, Wang Y, et al. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. JAMA. 2026. PMID: 42925007. doi:10.1001/jama.2026.21372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。